BioVie to Participate at the B. Riley Securities’ Neuro & Ophthalmology Conference

Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI) announced its management team's participation in the virtual B. Riley Securities’ Neuro & Ophthalmology Conference on April 27-28, 2022. CEO Cuong Do and CMO Joseph Palumbo will discuss the novel mechanism of action of NE3107, BioVie’s lead compound targeting Alzheimer’s and Parkinson’s diseases. The fireside chat is scheduled for April 28, 2022, at 1:30 PM ET. Additionally, BioVie is advancing its drug candidate BIV201 for liver disease, with anticipated Phase 2 study results expected in early 2023.

CARSON CITY, Nev., April 25, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the participation of its management team in a fireside chat and one-on-one meetings at the B. Riley Securities’ Neuro & Ophthalmology Conference, to be held virtually April 27-28, 2022.

Cuong Do (President and Chief Executive Officer) and Joseph Palumbo (Chief Medical Officer) will discuss the novel mechanism of action for NE3107, BioVie’s lead compound for the treatment of Alzheimer’s Disease and Parkinson’s disease.

Details on the fireside chat can be found below.

B. Riley Securities’ Neuro & Ophthalmology Conference
Presentation Date: Thursday, April 28, 2022
Presentation Time: 1:30 PM ET
Webcast Link: https://www.webcaster4.com/Webcast/Page/2875/45374

About BioVie
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2 study for the treatment of refractory ascites due to liver cirrhosis with top-line results anticipated in early 2023. BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not available in the US or Japan. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFB (e.g., TNF transcription) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in subjects who have mild to moderate Alzheimer's disease (NCT04669028). An estimated six million Americans suffer from Alzheimer’s. BioVie has initiated this study and is targeting primary completion in early 2023. A Phase 2 study of NE3107 in Parkinson’s disease is enrolling patients and expect to have topline data readout by mid-year 2022. NE3107 is patented in the United States, Australia, Canada, Europe, and South Korea. For more information, visit http://www.bioviepharma.com/.

For Investor Relations Inquiries: 

Contact:  Bruce Mackle  Managing Director  LifeSci Advisors, LLC  bmackle@lifesciadvisors.com

FAQ

What is BioVie's participation in the B. Riley Securities’ Neuro & Ophthalmology Conference?

BioVie Inc. will participate in the virtual B. Riley Securities’ Neuro & Ophthalmology Conference on April 27-28, 2022, discussing NE3107, its lead compound for Alzheimer’s and Parkinson’s diseases.

When is the fireside chat featuring BioVie management?

The fireside chat with BioVie management is scheduled for April 28, 2022, at 1:30 PM ET.

What are the key drug candidates being discussed by BioVie?

BioVie will discuss NE3107 for neurodegenerative diseases and BIV201 for liver disease at the conference.

What is the status of BioVie’s NE3107 clinical trials?

BioVie is conducting a Phase 3 study of NE3107 for mild to moderate Alzheimer’s disease and a Phase 2 study for Parkinson’s disease, with topline data expected mid-2022.

What is BIV201 and its significance?

BIV201 is an orphan drug candidate being evaluated in a Phase 2 study for treating refractory ascites due to liver cirrhosis, with results anticipated in early 2023.